Navilyst Medical to distribute VasoNova's VPS central venous catheter navigation technology

NewsGuard 100/100 Score

VasoNova (VasoNova Inc., Menlo Park, California) announced a strategic partnership with Navilyst Medical Inc. (Navilyst Medical Inc., Marlborough, Massachusetts) today to distribute its VasoNova™ Vascular Positioning System™ VPS™ central venous catheter navigation technology.

Commenting on the partnership, Navilyst Senior Vice President, George Bourne said "Navilyst Medical is a market and technology leader in vascular access and fluid management with a long tradition of therapeutic innovation. Accurate catheter tip location is clinically beneficial to the patient and directly contributes to lowering healthcare costs. These two things are firmly aligned with our mission and reflected in our many other market leading innovations in vascular access. We are very excited to be bringing the VasoNova™ VPS™ catheter navigation technology to our customers. The combination of best-in-class central venous catheters from Navilyst and real time catheter tip positioning of this caliber from VasoNova provides the best possible solution to our clinicians and for our patients".    

Paul Molloy, President & Chief Executive Officer at VasoNova added, "VasoNova's VPS™ technology is the first real-time intra-vascular catheter navigation technology that does not require external metal detectors or viewing screens, nor subjective interpretation of ECG signals, and is capable of confirming precise catheter tip location using highly sophisticated anatomical location identification algorithms embedded in its technology. These location signatures are identified utilizing highly specific Doppler ultrasound characteristics combined with other patient data. The VasoNova™ VPS™ is compatible with all commonly used PICC and CVC catheters. Navilyst's world-class vascular access product offering is highly synergistic and together we offer clinicians unparalleled technological advantages".

SOURCE VasoNova Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutations